

Conference Cochairs:

Peter J. Allen, Duke University School of Medicine, Durham, NC

Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA

Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

Alec C. Kimmelman, NYU Langone Health, New York, NY

SUNDAY, SEPTEMBER 15**Registration**

3-8 p.m. | America Ballroom Foyer

Welcome and Keynote Lectures

5:30-7:15 p.m. | American Ballroom Center & North | CME Eligible

- | | |
|-----------|--|
| 5:30-5:45 | Welcome
Peter J. Allen, Duke University School of Medicine, Durham, NC |
| 5:45-5:50 | Introduction of Keynote Speaker
Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA |
| 5:50-6:30 | Pancreas Cancer 2024: Translating genomic findings into clinical actionability
Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY |
| 6:30-6:35 | Introduction of Rising Star Keynote Speaker
Alec C. Kimmelman, NYU Langone Health, New York, NY |
| 6:35-7:15 | Targeting autophagy in pancreatic cancer
Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, MA |

Lightning Presentation Session A

7:20-7:40 p.m. | American Ballroom Center & North | CME Eligible

- | | |
|-----------|---|
| 7:20-7:25 | Introduction of Lightning Presentation Speakers
Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE |
| 7:25-7:27 | Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody
Diana Martinez-Saucedo, Yale University School of Medicine, New Haven, CT* |

** talk from proffered paper*

- 7:28-7:30 Uncovering molecular differences in pancreatic ductal adenocarcinoma tissues from Black and White patients in the US
Saurabh Mandal, Henry Ford Health, Detroit, MI*
- 7:31-7:33 Canonical Notch signaling in cancer-associated fibroblasts supports an immunosuppressive pancreatic tumor microenvironment
Allison Bischoff, University of Michigan, Ann Arbor, MI*
- 7:34-7:36 Phase 2 trial testing the PARP inhibitor Niraparib in patients with advanced pancreatic cancer with pathogenic variants in *BRCA 1*, *BRCA2*, *PALB2*, *ATM*, and *CHEK2*
Brandon Huffman, Dana-Farber Cancer Institute, Boston, MA*

Poster Session A / Reception

7:45-10 p.m. | American Ballroom South

MONDAY, SEPTEMBER 16

Continental Breakfast

7-8 a.m. | Essex Ballroom (3rd Floor)

Career Development Roundtable Session

7-8 a.m. | Essex Ballroom (3rd Floor) | Not CME Eligible

Attendance to each of the Career Roundtables will be on a first-come, first-served basis and no pre-registration is required. Participants may rotate to as many tables as they like during the session, providing the opportunity to network and interact with a diverse cadre of experts.

Balancing Clinical and Research Life Jashodeep Datta, University of Miami Miller School of Medicine, Miami, FL	How to Get a Paper Published Cosimo Commisso, Sanford Burnham Prebys, San Diego, CA Harmony Turk, <i>Cancer Research</i> , American Association for Cancer Research, Philadelphia, PA
Balancing Clinical and Research Life Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY	How to Get a Paper Published Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, OR

* talk from proffered paper

Careers in Industry Mallika Singh, Revolution Medicines, Redwood City, CA	How to Write a Grant Kirsten Bryant, University of North Carolina, Chapel Hill, NC
Choosing a Career Path: Academia vs. Industry Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC	How to Write a Grant Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI
Collaborating with Industry Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY	Starting Your Lab Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, MA
	Starting Your Lab Erica D. Pratt, Boston University, Boston, MA

Plenary Session 1: Cachexia, Diet, and Metabolism

8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, NC

8:15-8:20	Introduction Peter J. Allen
8:20-8:40	Mechanisms of pancreatic cancer cachexia Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, OR
8:40-8:45	Discussion / Q&A
8:45-9:05	Developing therapies for pancreatic cancer cachexia Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles, CA
9:05-9:10	Discussion / Q&A
9:10-9:30	Neuroendocrine causes and effects of cachexia Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
9:30-9:35	Discussion / Q&A
9:35-9:45	Endocrine beta-cell stress promotes pancreatic ductal adenocarcinoma through endocrine-exocrine cell crosstalk Cathy Garcia, Yale University, New Haven, CT*

* talk from proffered paper

9:45-9:55 Dietary fats dictate pancreatic cancer fate via phospholipid saturation
Christian Ruiz, Yale University, New Haven, CT*

Break

9:55-10:30 a.m. | American Ballroom Foyer

Plenary Session 2: Immunology and Immunotherapy

10:30 a.m.-12:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

10:30-10:35	Introduction Alec C. Kimmelman
10:35-10:55	The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as revealed by single-cell sequencing Rienk Offringa, German Cancer Research Center, Heidelberg, Germany
10:55-11	Discussion / Q&A
11-11:20	Investigating the role of CD4 T cells in the pancreatic tumor microenvironment Katelyn T. Byrne, Oregon Health and Science University, Portland, OR
11:20-11:25	Discussion / Q&A
11:25-11:45	Exploiting functional specialization of myeloid-derived suppressor cells to overcome therapeutic resistance in pancreatic cancer Jashodeep Datta, University of Miami Miller School of Medicine, Miami, FL
11:45-11:50	Discussion / Q&A
11:50-12	Discovery and therapeutic potential of novel cryptic peptides in pancreatic cancer Gurcan Gunaydin, Dana-Farber Cancer Institute, Boston, MA*
12:00-12:10	Reprogramming and selective recruitment of distinct neutrophil subpopulations restrain cancer metastasis Jae Lee, Johns Hopkins University School of Medicine, Baltimore, MD*

Lunch on Own

12:10-2:30 p.m.

** talk from proffered paper*

Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment

2:30-4:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

2:30-2:35	Introduction Michael A. (Tony) Hollingsworth
2:35-2:55	Functional heterogeneity of fibroblast populations in pancreatic cancer Giulia Biffi, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom
2:55-3	Discussion / Q&A
3-3:20	Mechanisms and consequences of pancreatic cancer stromal evolution Mara Sherman, Memorial Sloan Kettering Cancer Center, New York, NY
3:20-3:25	Discussion / Q&A
3:25-3:45	Targeting the tumor microenvironment to improve responses to therapy David G. DeNardo, Washington University School of Medicine in St. Louis, St. Louis, MO
3:45-3:50	Discussion / Q&A
3:50-4	Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response Paul Timpson, The Garvan Institute of Medical Research, Sydney, NSW, Australia*
4-4:10	Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy Max Wattenberg, University of Pennsylvania, Philadelphia, PA*

Lightning Presentation Session B

4:15-4:35 p.m. | American Ballroom Center & North | CME Eligible

4:15-4:20	Introduction of Lightning Presentation Speakers Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA
4:20-4:22	Altered mRNA splicing mimics chromosome loss and drives pancreatic cancer Natasha Pinto Medici, Yale University, New Haven, CT*

** talk from proffered paper*

- | | |
|-----------|--|
| 4:23-4:25 | The circadian rhythm gene Dec2 regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion
Chris Harris, University of Rochester Medical Center, Rochester, NY* |
| 4:26-4:29 | Disruption of sulfatide metabolism by targeting UGT8 is actionable metabolic vulnerability for pancreatic cancer early interception
Riccardo Ballaro, The University of Texas MD Anderson Cancer Center, Houston, TX* |
| 4:30-4:32 | Meta-analysis of spatial transcriptomics data from pancreatic cancer precursors propose a common molecular framework for PanIN and IPMN
Matthew Iyer, University of Michigan, Ann Arbor, MI* |

Poster Session B / Reception

4:45-7 p.m. | American Ballroom South

Dinner on Own

7 p.m.

TUESDAY, SEPTEMBER 17

Continental Breakfast

7-8 a.m. | Essex Ballroom (3rd Floor)

Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics

8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

- | | |
|-----------|--|
| 8:15-8:20 | Introduction
Alec C. Kimmelman |
| 8:20-8:40 | Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA |
| 8:40-8:45 | Discussion / Q&A |
| 8:45-9:05 | Adaptation and resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma
Kenneth P. Olive, Columbia University Irving Medical Center, New York, NY |
| 9:05-9:10 | Discussion / Q&A |

** talk from proffered paper*

9:10-9:30	Targeting the oncogenic state of RAS with tri-complex inhibitors Mallika Singh, Revolution Medicines, Redwood City, CA
9:30-9:35	Discussion / Q&A
9:35-9:45	Identifying synergistic combinations with KRAS inhibition in PDAC Fredrik Thege, The University of Texas MD Anderson Cancer Center, Houston, TX*
9:45-9:55	Evaluating direct KRAS ^{Q61H} inhibition in pancreatic cancer models Andrew Waters, University of Cincinnati, Cincinnati, OH*

Break

9:55-10:30 a.m. | American Ballroom Foyer

Plenary Session 5: KRAS Cell Biology

10:30-11:50 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

10:30-10:35	Introduction Michael A. (Tony) Hollingsworth
10:35-10:55	Targeting KRAS for pancreatic cancer treatment Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC
10:55-11	Discussion / Q&A
11-11:20	Elucidation of metabolic resistance mechanisms to RAS inhibition Kirsten Bryant, University of North Carolina, Chapel Hill, NC
11:20-11:25	Discussion / Q&A
11:25-11:45	RAS mutation tropism: Insight into tumor initiation Christopher M. Counter, Duke University School of Medicine, Durham, NC
11:45-11:50	Discussion / Q&A

Lunch on Own / Free Time

11:50 a.m.-2:30 p.m.

** talk from proffered paper*

Plenary Session 6: Early Detection and Interception of Precursor Lesions

2:30-4:15 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, NC

2:30-2:35	Introduction Peter J. Allen
2:35-2:55	Prevention of pancreatic cancer: The opportunity of intraductal papillary mucinous neoplasms Peter J. Allen
2:55-3	Discussion / Q&A
3-3:20	Multimodal tools for noninvasive cancer monitoring Erica D. Pratt, Boston University, Boston, MA
3:20-3:25	Discussion / Q&A
3:25-3:45	Improving pancreatic cancer early detection using a tumor marker gene test Michael G. Goggins, Johns Hopkins University, Baltimore, MD
3:45-3:55	Discussion / Q&A
3:55-4:05	Genomic and transcriptomic characterization of pancreatic cancer patients on the PASS-01 trial Grainne O’Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada*
4:05-4:15	Tracing pancreatic cancer through space Eileen Carpenter, University of Michigan, Ann Arbor, MI

Break

4:15-4:35 p.m. | American Ballroom Foyer

Plenary Session 7: Tumor Cell Biology

4:35-6 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

4:35-4:40	Introduction Michael A. (Tony) Hollingsworth
4:40-5	Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer Wantong Yao, The University of Texas MD Anderson Cancer Center, Houston, TX

** talk from proffered paper*

5-5:10	Discussion / Q&A
5:10-5:30	Stress-induced O-glycans drive immunosuppression in pancreatic cancer Tobiloba Oni, Whitehead Institute, Cambridge, MA
5:30-5:35	Discussion / Q&A
5:35-5:55	Metabolic adaptations to autophagy inhibition in PDAC Christina Towers, The Salk Institute for Biological Studies, La Jolla, CA
5:55-6	Discussion / Q&A

Lightning Presentation Session C

6-6:15 p.m. | American Ballroom Center & North | CME Eligible

6-6:05	Introduction of Lightning Presentation Speakers Peter J. Allen, Duke University School of Medicine, Durham, NC
6:05-6:07	RNF43 loss induces an IRE1-dependent metabolic reprogramming in pancreatic cystic neoplasms Akiko Sagara, The University of Texas MD Anderson Cancer Center, Houston, TX*
6:08-6:10	Cell polarity proteins as novel regulators of macropinocytosis Guillem Lambies Barjau, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA*
6:11-6:13	Hepcidin-mediated iron sequestration limits CD8 ⁺ tumor infiltrating lymphocytes in pancreas adenocarcinoma Joshua Schoenfeld, Memorial Sloan Kettering Cancer Center, New York, NY*

Poster Session C / Reception

6:30-9 p.m. | American Ballroom South

WEDNESDAY, SEPTEMBER 18

Continental Breakfast

7-8 a.m. | Essex Ballroom (3rd Floor)

Plenary Session 8: Plasticity

8-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA

8-8:20	TGFβ in pancreatic cancer Stephanie K. Dougan
--------	--

** talk from proffered paper*

8:20-8:25	Discussion / Q&A
8:25-8:45	Regulation of tumor and stromal cell plasticity by metabolic stress Cosimo Commisso, Sanford Burnham Prebys, San Diego, CA
8:45-8:50	Discussion / Q&A
8:50-9:10	The role of methionine oxidation in pancreatic tumorigenesis Christine Chio, Columbia University, New York, NY
9:10-9:15	Discussion / Q&A
9:15-9:35	PDAC proteomic subtype specification through the lens of racial health disparities Nicholas T. Woods, University of Nebraska Medical Center, Omaha, NE
9:35-9:40	Discussion / Q&A
9:40-9:50	Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer Harshabad Singh, Dana-Farber Cancer Institute, Boston, MA*
9:50-9:55	Discussion / Q&A

Break

9:55-10:15 a.m. | American Ballroom Foyer

Plenary Session 9: Metabolism

10:15-11:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

10:15-10:20	Introduction Alec C. Kimmelman
10:20-10:40	Identifying metabolic dependencies in pancreatic cancer Alec C. Kimmelman
10:40-10:45	Discussion / Q&A
10:45-11:05	Spatiotemporal metabolic networks in pancreatic cancer and associated cachexia Nada Kalaany, Harvard Medical School / Boston Children's Hospital, Boston, MA
11:05-11:10	Discussion / Q&A
11:10-11:30	Targeting lipid metabolism in pancreatic cancer Costas A. Lyssiotis, University of Michigan Medical School, Ann Arbor, MI
11:30-11:35	Discussion / Q&A

* talk from proffered paper

11:35-11:50 Metabolic competition in pancreatic tumor microenvironment regulates innate immune responses
Kamiya Mehla, University of Oklahoma Health Sciences Center, Oklahoma City, OK
11:50-11:55 Discussion / Q&A

Debate: Have We Learned Anything from the KRAS Inhibitors That We Didn't Already Know from Mice?

12:00-12:45 p.m. | American Ballroom Center & North | CME Eligible

Moderator: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI

Departure

12:45 p.m.

** talk from proffered paper*